1. Home
  2. EYE vs LBRX Comparison

EYE vs LBRX Comparison

Compare EYE & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo National Vision Holdings Inc.

EYE

National Vision Holdings Inc.

SELL

Current Price

$18.76

Market Cap

1.4B

Sector

Health Care

ML Signal

SELL

Logo LB Pharmaceuticals Inc

LBRX

LB Pharmaceuticals Inc

SELL

Current Price

$42.98

Market Cap

1.2B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
EYE
LBRX
Founded
1990
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Ophthalmic Goods
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.2B
IPO Year
2017
2025

Fundamental Metrics

Financial Performance
Metric
EYE
LBRX
Price
$18.76
$42.98
Analyst Decision
Buy
Strong Buy
Analyst Count
11
11
Target Price
$27.00
★ $58.00
AVG Volume (30 Days)
★ 2.1M
318.4K
Earning Date
11-12-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 202.78
98.22
EPS
★ 0.78
N/A
Revenue
★ $1,987,488,000.00
N/A
Revenue This Year
$2.20
N/A
Revenue Next Year
$4.73
N/A
P/E Ratio
$23.32
★ N/A
Revenue Growth
★ 9.00
N/A
52 Week Low
$14.75
$15.19
52 Week High
$30.02
$50.16

Technical Indicators

Market Signals
Indicator
EYE
LBRX
Relative Strength Index (RSI) 58.15 56.82
Support Level $15.52 $37.99
Resistance Level $20.98 $49.74
Average True Range (ATR) 1.13 2.53
MACD 0.11 0.36
Stochastic Oscillator 84.35 63.95

Price Performance

Historical Comparison
EYE
LBRX

About EYE National Vision Holdings Inc.

National Vision Holdings Inc. is an optical retailer in the United States. Its product portfolio includes eyeglasses, sunglasses, contact lenses, accessories, and other related products. The company operates through a single operating segment. The Owned and Host segment includes the company-owned brands America's Best and Eyeglass World. In America's Best stores, vision care services are provided by optometrists or by independent professional corporations. The Host segment consists of Military and Fred Meyer locations, where eye exams are provided by independent optometrists.

About LBRX LB Pharmaceuticals Inc

LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.

Share on Social Networks: